LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
BALLERUP, Denmark, April 11, 2019 – LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50,000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies. In addition to LEO Pharma the team comprises 26 academic and five industry partners as well as five patient organisations. The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology.
Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems. Yet, despite many years of research, there are still significant gaps in the understanding of both conditions.
The renowned clinicians and scientists of BIOMAP, who have now joined forces in a large public-private partnership, will examine the causes and mechanisms of these conditions. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics. BIOMAP is the first IMI project in the field of dermatology.
“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases”, says Dr Witte Koopmann, industrial co-project lead from LEO Pharma.
Professor Stephan Weidinger, academic coordinator of the consortium and internationally-renowned clinician scientist from the University of Kiel Germany, hopes that “atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”
“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene”, expects BIOMAP’s academic co-coordinator Professor Catherine Smith from King’s College London.
The voices of patients living with Atopic Dermatitis and Psoriasis will be at the heart of BIOMAP, through the establishment of a Patient Advisory Group. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.
BIOMAP is funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The project will officially kick off its activities with a first meeting in London on 10-12 April, 2019.
EURICE – European Research and Project Office GmbH
Dr Verena Peuser
Phone +49 30 374415832
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
Information om LEO Pharma
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CEST | Pressemeddelelse
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CET | Pressemeddelelse
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors28.2.2019 00:10:03 CET | Pressemeddelelse
BALLERUP, Denmark, 28 February 2019 – LEO Pharma today announced changes to its Board of Directors. Olivier Bohuon is announced new chairman of the Board of Directors succeeding Jukka Pertola, who has decided to leave the Board. Member of the Board Anders Ekblom will assume a new position as vice chairman. In addition, John Weeks decided to not seek re-election.
LEO Pharma Annual Results 2018: A year in line with expectations28.2.2019 00:08:59 CET | Pressemeddelelse
- 2018 revenue of DKK 10,410 million - Strong progress on 2025 Strategy - Strengthened innovative clinical pipeline - Expanded established portfolio
Forskere fra LEO Pharma hyldes med Innovationsfondens Innovatørpris 20191.2.2019 15:01:40 CET | Pressemeddelelse
Excellent og banebrydende forskning, som skaber værdi for Danmark, er i fokus, når Innovationsfonden i dag uddeler årets priser. Det er derfor med stor stolthed, at LEO Pharma i dag kan meddele, at to af virksomhedens forskere, Marianne Lind, Ph.d. Senior Scientist og Karsten Petersson, Ph.d. Director, er udvalgt til at modtage Innovatørprisen 2019. Det er tredje år i træk, at prisen uddeles, og tildelingen af årets Innovatørpris til Marianne Lind og Karsten Petersson, som begge arbejder inden Explorative Formulation & Technologies hos LEO Pharma, sker på baggrund af følgende vurderinger: Den værdiskabelse, kandidaterne har skabt for såvel virksomhed som patienter Kandidaternes evne til at omsætte excellent forskningsviden til konkrete løsninger De to forskere modtager prisen for udviklingen af Enstilar®, LEO Pharmas skumspray til behandling af psoriasis. Enstilar® blev godkendt af Lægemiddelstyrelsen og kom på markedet i Danmark i 2016. Produktet anvendes i dag af flere end en million
LEO Pharma further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine28.1.2019 10:15:51 CET | Pressemeddelelse
Ballerup, Denmark, 28 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Thomas Hultsch, M.D., Ph.D., has been appointed as Head of Translational Medicine as of 28 January, 2019.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum